Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 111–120, page 12 of 20. Filter these by subject, year and score in the research library →

1. Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern ChinaResearch summary

   Research summaries · alzhub.org/study/real-world-experience-with-baseline-characteristics-and-safety-of-41396015

   … preliminary safety of lecanemab for AD in Zhejiang Province, and to evaluate the efficacy of plasma biomarkers for patient screening.MethodsThis multi-center study included 190 patients with AD in Zhejiang Province, who completed …

2. Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experienceResearch summary

   Research summaries · alzhub.org/study/real-world-implementation-of-lecanemab-and-donanemab-in-an-italian-41857623

   … ARIA-H in 15% (3/20). In lecanemab-treated patients, asymptomatic ARIA-H occurred in 11% (1/9). Infusion-related reactions occurred in 21% (6/29) of treatment courses and were manageable with standardized premedication. Among 11 …

3. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpointResearch summary

   Research summaries · alzhub.org/study/the-affordability-of-lecanemab-an-amyloid-targeting-therapy-for-37251789

   Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate …

4. The social value of lecanemab for patients with early Alzheimer's disease in JapanResearch summary

   Research summaries · alzhub.org/study/the-social-value-of-lecanemab-for-patients-with-early-alzheimer-s-42108615

   … the social value of lecanemab in Japan.MethodsThe social value was evaluated using a cost-effectiveness model. The intervention was lecanemab added to the standard of care (SOC), and the comparator was SOC alone. The effect of …

5. A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databasesResearch summary

   Research summaries · alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431

   Background Lecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer's disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited …

6. Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?Research summary

   Research summaries · alzhub.org/study/are-deep-white-matter-hyperintensities-associated-with-amyloid-41038644

   … with AD treated with lecanemab. These findings suggest that DWMH may serve as a potential imaging biomarker for ARIA risk stratification. Larger studies incorporating additional vascular biomarkers, including cerebral amyloid …

7. Baseline Amyloid PET Centiloid Score and Risk of Amyloid-Related Imaging Abnormalities in Patients Treated With LecanemabResearch summary

   Research summaries · alzhub.org/study/baseline-amyloid-pet-centiloid-score-and-risk-of-amyloid-related-42595466

   … patients treated with lecanemab and included a secondary exploratory analysis of regional amyloid uptake. Materials and methods We retrospectively identified patients treated with lecanemab within a single academic health system …

8. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatmentResearch summary

   Research summaries · alzhub.org/study/commentaries-lecanemab-pioneering-the-way-as-the-first-approved-drug-37682322

   … disease progression. Lecanemab, an anti-amyloid antibody, binds to amyloid-beta (Aβ) protofibrils. Phase II trials revealed dose-dependent amyloid clearance and reduced clinical decline. Phase III trials demonstrated cognitive …

9. Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world studyResearch summary

   Research summaries · alzhub.org/study/effectiveness-safety-and-biomarker-dynamics-of-lecanemab-in-chinese-41823189

   Lecanemab significantly attenuated cognitive decline versus ADNI. Plasma Aβ42, Aβ40, phosphorylated tau 217 (p‑tau217), glial fibrillary acidic protein (GFAP), and ratios showed robust changes; a p‑tau217 reduction correlated …

10. Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in FranceResearch summary

    Research summaries · alzhub.org/study/estimating-the-eligible-population-for-amyloid-targeting-monoclonal-42874425

    Lecanemab was the first amyloid-targeting monoclonal antibody approved by the European Commission for treating patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). While this marketing …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.